Recent Updates
Recently added Catalysts
ACOG Positive Sentiment

Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms

Key Takeaway: Alpha Cognition Inc. announced the publication of its U.S. patent application for Benzgalantamine, aimed at treating persistent post-concussion symptoms. The patent, numbered 20260325541-A1, includes claims directed towards this treatment. This development represents a significant step in the company's efforts to address neurodegenerative disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication of a new patent application.
  • Focus on treating persistent post-concussion symptoms.
  • Potential for novel therapeutics in neurodegenerative disorders.

Full Press Release Details

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled “Benzgalantamine for Treating Persistent Post-Concussion Symptoms.”The published application includes pending claims directe

Frequently Asked Questions

What is the patent application for?

It covers benzgalantamine for treating persistent post-concussion symptoms.

Which company published the patent?

Alpha Cognition Inc. published the application with the USPTO.

What is the patent number?

The published patent number is 20260325541-A1.

Where was the announcement issued?

Alpha Cognition issued the announcement from Vancouver, British Columbia.

Last updated: Nov 16, 2026